Encouraging the scientific community to use proteomics technologies to study type 1 diabetes (T1D) and its complications. Proteomic technologies have been successfully used for the identification of cancer biomarkers, for the identification of novel drug targets and for studying several biological processes relevant to human health. High throughput metabolic profiling has been recently implemented for metabolomic studies. However, as of today these technologies have been applied to study T1D and its complication only in a limited way. Moreover, currently available proteomic and metabolomic technologies represent a great opportunity for advancing the field of T1D and its complications.